Table 2 Clinical characteristics (A) and outcomes (B) in the cohort of breast cancer patients (N = 457) and their correlation with BRCA mutation and non-BRCA mutation carrying status
From: Germline breast cancer susceptibility gene mutations and breast cancer outcomes
| Â | No mutation | BRCA mutation | Non-BRCA mutation | |||
|---|---|---|---|---|---|---|
N = 397 | N = 36 | P-value* | N = 24 | P-value* | ||
A. Clinical characteristics | ||||||
Age of onset, mean (SD) | Â | 41.7 (9.9) | 42.1 (10.1) | 0.846 | 42.3 (11.4) | 0.771 |
| Â | Â | no. (%) | no. (%) | Â | no. (%) | Â |
Lymph node | positive | 160 (42.6) | 20 (66.7) | 0.011 | 8 (36.4) | 0.568 |
negative | 216 (57.5) | 10 (33.3) | Â | 14 (63.6) | Â | |
Tumor size | ≤ 2 cm | 194 (52.3) | 16(55.2) | 0.765 | 13 (59.1) | 0.535 |
>  2 cm | 177 (47.7) | 13 (44.8) |  | 9 (40.9) |  | |
Surgery type | MRM | 246 (62.1) | 29 (80.6) | 0.028 | 14 (58.3) | 0.711 |
BCT | 150 (37.9) | 7 (19.4) | Â | 10 (41.7) | Â | |
Chemotherapy | yes | 323 (82.0) | 36 (100) | 0.005 | 17 (70.8) | 0.174 |
no | 71 (18.0) | 0 (0) | Â | 7 (29.2) | Â | |
Radiotherapy | yes | 275 (69.8) | 29 (82.9) | 0.103 | 16 (66.7) | 0.746 |
no | 119 (30.2) | 6 (17.1) | Â | 8 (33.3) | Â | |
Hormonal therapy | yes | 217 (57.7) | 21 (70) | 0.189 | 12 (54.5) | 0.770 |
no | 159 (42.3) | 9 (30) | Â | 10 (45.5) | Â | |
Stage | 0 (DCIS) | 11 (2.8) | 0 (0) | 0.307 | 1 (4.2) | 0.704 |
1 | 138 (35.0) | 8 (23.5) | Â | 11 (45.8) | Â | |
2 | 159 (40.4) | 15 (44.1) | Â | 10 (41.7) | Â | |
3 | 48 (12.2) | 8 (23.5) | Â | 1 (4.2) | Â | |
4 | 7 (1.8) | 0 (0) | Â | 0 (0) | Â | |
LABC | 31 (7.9) | 3 (8.8) | Â | 1 (4.2) | Â | |
Triple negative | yes | 108 (27.2) | 9 (25.0) | 0.776 | 9 (37.5) | 0.274 |
no | 289 (72.8) | 27 (75.0) | Â | 15 (62.5) | Â | |
ER | positive | 234 (59.5) | 24 (66.7) | 0.403 | 12 (52.2) | 0.485 |
negative | 159 (40.5) | 12 (33.3) | Â | 11 (47.8) | Â | |
HER2 overexpression | yes | 72 (19.8) | 3 (8.8) | 0.118 | 3 (14.3) | 0.537 |
no | 292 (80.2) | 31 (91.2) | Â | 18 (85.7) | Â | |
Nuclear grade | 1 | 51 (13.9) | 1 (3.5) | 0.276 | 3 (14.3) | 0.896 |
2 | 123 (33.5) | 11 (37.9) | Â | 8 (38.1) | Â | |
3 | 193 (52.6) | 17 (58.6) | Â | 10 (47.6) | Â | |
Lymphovascular invasion | prominent | 82 (22.1) | 11 (37.9) | 0.122 | 2 (9.5) | 0.259 |
focal | 104 (28.0) | 8 (27.6) | Â | 5 (23.8) | Â | |
absent | 185 (49.9) | 10 (34.5) | Â | 14 (66.7) | Â | |
B. Outcomes | ||||||
Recurrence†| 53 (13.4) | 11 (30.6) | 0.005 | 1 (4.2) | 0.191 | |
 Distant metastasis | 38 (9.6) | 9 (25.0) | 0.004 | 0 (0) | 0.112 | |
 Locoregional recurrence only | 15 (3.8) | 2 (5.6) | 0.599 | 1 (4.2) | 0.923 | |
Death | 12 (3.0) | 3 (8.3) | 0.095 | 0 (0) | 0.388 | |